Results 91 to 100 of about 14,850 (194)

Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report

DEN Open, Volume 6, Issue 1, April 2026.
Abstract A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration.
Satoshi Kosaka, Miki Kamiyama, Masahiro Ochi   +2 more
wiley   +1 more source

The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta‐Analysis

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
SGLT2 inhibitors reduce skeletal muscle mass modestly in older adults with type 2 diabetes. Forest plot (a) and count our funnel plot (b) show a small but significant pooled reduction in muscle mass (SMD = −0.36, 95% CI [−0.56, −0.15]; I2 = 24.1%), with weight loss occurring predominantly through fat mass reduction.
Weena Joongpan, Nittaya Boonmuen, Pimthong Sinchai, Sarawut Lapmanee, Natawat Klamsakul, Nutthapoom Pathomthongtaweechai   +5 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT‐2 inhibitors

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aim To compare the clinical characteristics, biochemical presentation, and short‐ and long‐term outcomes of DKA in hospitalized adults with T1DM and T2DM, including the impact of SGLT2 inhibitor therapy. Methods A retrospective cohort of 2283 adults (838 with T1DM; 1445 with T2DM) hospitalized with DKA between 2013 and 2023 across Clalit ...
Elena Chertok Shacham, Sireen Sharif, Rageh Tatoor, Snait Ayalon   +3 more
wiley   +1 more source

Effects of dapagliflozin on inflammatory level and prognosis in patients with type 2 diabetes mellitus and acute myocardial infarction

Zhongguo Linchuang Yixue
ObjectiveTo investigate the effects of dapagliflozin on inflammatory factors and prognosis in patients with type 2 diabetes mellitus (T2DM) and acute myocardial infarction (AMI). MethodsIn a randomized, double-blind trial, 146 patients with T2DM and AMI (
Mengmei Li, Weifeng Zhang, Xiaowen Zhen, Weisheng Liu   +3 more
doaj   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2978-2987, April 2026.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Dapagliflozin effect on anemia outcomes in patients with diabetes and CKD

Future Journal of Pharmaceutical Sciences
Background Anemia is a prevalent complication in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), contributing to adverse clinical outcomes.
Ramy Ibrahim Elwaraky, Amira B. Kassem, Ahmed Fathi Elkeraie, Gamal Abdelhay Omran, Noha A. El‑Bassiouny   +4 more
doaj   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3033-3043, April 2026.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source